[{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||mAChR","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Yale University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine","moa":"||Muscarinic acetylcholine receptor M1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yale University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Repurposed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Scopolamine","moa":"||Muscarinic acetylcholine receptor M1","graph1":"Neurology","graph2":"Phase III","graph3":"Repurposed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Repurposed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Repurposed Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Boro Scopol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Yale University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Yale University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2023

                          Lead Product(s) : Scopolamine,11-C LSN3172176

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 12, 2022

                          Lead Product(s) : Atropine Sulfate,Scopolamine

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : IND Enabling

                          Sponsor : US Department of Defense

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 17, 2020

                          Lead Product(s) : Scopolamine,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 17, 2019

                          Lead Product(s) : Scopolamine,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 14, 2019

                          Lead Product(s) : Scopolamine,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Repurposed Therapeutics

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 14, 2019

                          Lead Product(s) : Scopolamine,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Taub Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Taub Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 29, 2017

                          Lead Product(s) : Scopolamine,Naltrexone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Medical Corps, Israel Defense Force

                          Country arrow
                          EPSC
                          Not Confirmed

                          Medical Corps, Israel Defense Force

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 01, 2017

                          Lead Product(s) : Scopolamine,Meclizine Hydrochloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Tetra Discovery Partners

                          Country arrow
                          EPSC
                          Not Confirmed

                          Tetra Discovery Partners

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 24, 2017

                          Lead Product(s) : Zatolmilast,Scopolamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2016

                          Lead Product(s) : Scopolamine,TAK-071

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank